FindTrial
Sign In

Treatment of warts in children with MMR vaccine

To study the efficacy of intralesional MMR (Measles-Mumps- Rubella virus) vaccine for the treatment of common warts:a case control study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/11/010344
Enrollment
55
Registered
2017-11-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Common warts

Interventions

Intervention1: MMR vaccine: MMR vaccine 0.25ml was injected in one largest wart using a 30G insulin syringe (one dose) and repeated at every 2-week interval until complete clearance or for a maximum o

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children and adolescents clinically diagnosed having untreated common warts

Exclusion criteria

Exclusion criteria: 1. Children with apparent infection or immunosuppression, asthma, allergic disorders, meningitis or convulsions 2. Children who have received treatment for warts in preceding month

Design outcomes

Primary

MeasureTime frame
The clinical improvement was evaluated as complete, partial or no response at each visitTimepoint: Once a month after completion of treatment for 6 months—

Secondary

MeasureTime frame
Evaluation for adverse effect and recurrencesTimepoint: Once a month after last dose for 6 months—

Countries

India

Contacts

Public ContactDr Vikram Mahajan
vkm1@rediffmail.com9418007941

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026